Want to see HK:9995 full AI Analyst Report?
9995 Stock Chart & Stats
HK$84.75
-HK$2.00(-2.36%)
At close: 4:00 PM EDT
HK$84.75
-HK$2.00(-2.36%)
Day’s Range― - ―
52-Week RangeHK$57.65 - HK$126.60
Previous CloseN/A
Volume0.00
Average Volume (3M)6.34M
Market Cap
HK$63.40B
Enterprise ValueHK$52.85K
Total Cash (Recent Filing)HK$2.74B
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)49.6
Beta1.52
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.29
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)10.96
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$120.78Price Target Upside42.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)6.14
Revenue Forecast (FY)HK$7.09B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundRemeGen’s shift to sustained profitability with ~21.8% EBIT and net margins is a durable improvement that supports reinvestment in commercialization and R&D, improves capital allocation and partner confidence, and provides a stronger earnings base to sustain operations over the next several quarters.
Strong Revenue GrowthDouble-digit top-line acceleration (≈80% reported) indicates strong market uptake and commercialization traction for RemeGen’s biologics. Sustained revenue expansion expands scale, helps cover fixed costs, and underpins durable margin maintenance and reinvestment capacity across the 2–6 month horizon.
Improved Leverage & High ROELeverage has meaningfully improved from prior highs and debt-to-equity (~0.61) with a strong ROE (~28%) reflects better capital efficiency. This moderate leverage profile reduces near-term refinancing pressure and provides balance sheet capacity to fund growth or partnerships over the medium term.
Bears Say
Weak Cash ConversionReported earnings are not translating into cash: operating cash flow is only ~2% of net income. Poor cash conversion undermines the sustainability of reported profits, constrains internal funding for commercialization and R&D, and increases reliance on external financing over the 2–6 month horizon.
Volatile Free Cash FlowFree cash flow has swung sharply and was negative across multiple prior years. Persistent FCF volatility makes capital planning difficult, raises the likelihood of dilutive or costly financing when scaling, and heightens execution risk for sustained investment in pipeline and commercial expansion.
Profitability Volatility HistoricallyHistorical swings from large losses to recent profits reduce predictability of earnings durability. For a biotech with commercialization and regulatory risk, volatile profitability complicates forecasting, partner negotiations, and long-term margin sustainability across planning cycles.
RemeGen Co. Ltd. Class H News
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$57.65 and its highest was HK$126.60 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$63.40B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Aug 25, 2026 which is in 21 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.672 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.672.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of HK$0.672 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.476%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$120.78 (42.52% Upside)
HK$120.78 (42.52% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
495.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.80%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
9995 Stock 12 Month Forecast
Average Price Target
HK$120.78
▲(42.52% Upside)
Technical Analysis
Akeso, Inc.
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―